10-Q: TG Therapeutics Reports First Quarter 2024 Results, Driven by Strong Briumvi Sales

TG Therapeutics' first quarter 2024 results show significant revenue growth driven by Briumvi sales and a milestone payment, alongside increased R&D spending.

Summary

• TG Therapeutics reported a net loss of $10.7 million for the first quarter of 2024, compared to a net loss of $39.2 million for the same period in 2023.
• Total revenue for the quarter was $63.5 million, a substantial increase from $7.8 million in the first quarter of 2023.
• Product revenue, primarily from Briumvi sales, reached $50.5 million, up from $7.8 million in the prior year.
• License, milestone, royalty, and other revenue totaled $13 million, including a $12.5 million milestone payment from Neuraxpharm.
• Research and development expenses increased to $32.7 million, compared to $15.9 million in the first quarter of 2023, due to the Precision BioSciences license agreement and manufacturing costs.
• Selling, general, and administrative expenses were $34.6 million, up from $28.1 million in the same period last year, primarily due to commercialization efforts for Briumvi.
• The company had $209.8 million in cash, cash equivalents, and investment securities as of March 31, 2024.
• TG Therapeutics believes its current resources will fund operations for at least the next twelve months.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth and a solid cash position, but also highlights increased expenses and risks associated with commercialization and development. The overall sentiment is cautiously optimistic.

Positives

• Briumvi sales are showing strong growth, indicating successful commercialization efforts.
• The milestone payment from Neuraxpharm validates the ex-U.S. commercialization strategy.
• The company has a solid cash position to support ongoing operations and development.
• The company has expanded its pipeline with the acquisition of azer-cel from Precision BioSciences.

Negatives

• The company continues to incur operating losses, although the net loss has decreased compared to the previous year.
• Research and development expenses have significantly increased, impacting overall profitability.
• Selling, general, and administrative expenses have also increased, reflecting the costs of commercialization.

Risks

• The company's future profitability depends on the continued success of Briumvi and other drug candidates.
• There are risks associated with relying on third-party manufacturers for product supply.
• The company faces competition from other pharmaceutical companies in the same therapeutic areas.
• Regulatory approvals for product candidates are subject to uncertainty and potential delays.
• The company's level of indebtedness and debt service obligations could adversely affect its financial condition.
• The company is subject to risks related to commercialization, drug development, regulatory approval, and intellectual property protection.

Future Outlook

The company believes its existing cash, cash equivalents, and investment securities, combined with projected revenues associated with the sale of BRIUMVI in the U.S. and ex-U.S., will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing.

Management Comments

• The company believes its existing cash, cash equivalents, and investment securities, combined with projected revenues associated with the sale of BRIUMVI in the U.S. and ex-U.S., will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing.

Industry Context

The company is operating in a competitive biopharmaceutical market, facing competition from companies with greater resources. The focus on B-cell diseases and the commercialization of Briumvi places the company in a growing market segment with significant potential but also substantial competition.

Comparison to Industry Standards

• The increase in revenue from Briumvi sales is a positive sign, indicating successful commercialization, which is a key metric for biopharmaceutical companies.
• The increase in R&D spending is typical for companies in the development phase, but the company will need to manage these costs effectively.
• The company's cash position is relatively strong, which is important for funding ongoing operations and development programs.
• Compared to other companies in the biopharmaceutical sector, TG Therapeutics is in a transition phase from a research-focused company to a commercial entity, and its performance will be closely watched by investors.
• The company's reliance on third-party manufacturers is common in the industry, but it introduces risks that need to be managed carefully.

Related Party Transactions

• The company incurred expenses of approximately $0.6 million related to shared personnel with Fortress Biotech, Inc.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and potential for future growth.
• Employees will be impacted by the company's expansion and commercialization efforts.
• Patients will benefit from the availability of Briumvi and other potential therapies.
• Suppliers and creditors will be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Continue commercialization efforts for Briumvi in the U.S. and Europe.
• Advance the development of other drug candidates, including TG-1701, TG-1801, and azer-cel.
• Manage manufacturing and supply chain to meet commercial demand.
• Monitor and manage expenses to achieve profitability.
• Evaluate additional strategic opportunities for growth.

Key Dates

Keywords

Briumvi, ublituximab, multiple sclerosis, RMS, TG Therapeutics, pharmaceutical, biotechnology, revenue, clinical trials, regulatory approval, commercialization, Neuraxpharm, azer-cel, Precision BioSciences